Integrated mapping of pharmacokinetics and pharmacodynamics in a patient-derived xenograft model of glioblastoma

Elizabeth C. Randall, Kristina B. Emdal, Janice K. Laramy, Minjee Kim, Alison Roos, David Calligaris, Michael S. Regan, Shiv K. Gupta, Ann C. Mladek, Brett L. Carlson, Aaron J. Johnson, Fa Ke Lu, X. Sunney Xie, Brian A. Joughin, Raven J. Reddy, Sen Peng, Walid M. Abdelmoula, Pamela R. Jackson, Aarti Kolluri, Katherine A. Kellersberger & 8 others Jeffrey N. Agar, Douglas A. Lauffenburger, Kristin Swanson, Nhan Tran, William F. Elmquist, Forest M. White, Jann N Sarkaria, Nathalie Y.R. Agar

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Therapeutic options for the treatment of glioblastoma remain inadequate despite concerted research efforts in drug development. Therapeutic failure can result from poor permeability of the blood-brain barrier, heterogeneous drug distribution, and development of resistance. Elucidation of relationships among such parameters could enable the development of predictive models of drug response in patients and inform drug development. Complementary analyses were applied to a glioblastoma patient-derived xenograft model in order to quantitatively map distribution and resulting cellular response to the EGFR inhibitor erlotinib. Mass spectrometry images of erlotinib were registered to histology and magnetic resonance images in order to correlate drug distribution with tumor characteristics. Phosphoproteomics and immunohistochemistry were used to assess protein signaling in response to drug, and integrated with transcriptional response using mRNA sequencing. This comprehensive dataset provides simultaneous insight into pharmacokinetics and pharmacodynamics and indicates that erlotinib delivery to intracranial tumors is insufficient to inhibit EGFR tyrosine kinase signaling.

Original languageEnglish (US)
Article number4904
JournalNature Communications
Volume9
Issue number1
DOIs
StatePublished - Dec 1 2018

Fingerprint

Pharmacodynamics
Pharmacokinetics
Glioblastoma
Heterografts
drugs
Pharmaceutical Preparations
Tumors
tumors
blood-brain barrier
Histology
sequencing
histology
tyrosine
Magnetic resonance
Blood-Brain Barrier
Protein-Tyrosine Kinases
inhibitors
Mass spectrometry
magnetic resonance
Permeability

ASJC Scopus subject areas

  • Chemistry(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Physics and Astronomy(all)

Cite this

Randall, E. C., Emdal, K. B., Laramy, J. K., Kim, M., Roos, A., Calligaris, D., ... Agar, N. Y. R. (2018). Integrated mapping of pharmacokinetics and pharmacodynamics in a patient-derived xenograft model of glioblastoma. Nature Communications, 9(1), [4904]. https://doi.org/10.1038/s41467-018-07334-3

Integrated mapping of pharmacokinetics and pharmacodynamics in a patient-derived xenograft model of glioblastoma. / Randall, Elizabeth C.; Emdal, Kristina B.; Laramy, Janice K.; Kim, Minjee; Roos, Alison; Calligaris, David; Regan, Michael S.; Gupta, Shiv K.; Mladek, Ann C.; Carlson, Brett L.; Johnson, Aaron J.; Lu, Fa Ke; Xie, X. Sunney; Joughin, Brian A.; Reddy, Raven J.; Peng, Sen; Abdelmoula, Walid M.; Jackson, Pamela R.; Kolluri, Aarti; Kellersberger, Katherine A.; Agar, Jeffrey N.; Lauffenburger, Douglas A.; Swanson, Kristin; Tran, Nhan; Elmquist, William F.; White, Forest M.; Sarkaria, Jann N; Agar, Nathalie Y.R.

In: Nature Communications, Vol. 9, No. 1, 4904, 01.12.2018.

Research output: Contribution to journalArticle

Randall, EC, Emdal, KB, Laramy, JK, Kim, M, Roos, A, Calligaris, D, Regan, MS, Gupta, SK, Mladek, AC, Carlson, BL, Johnson, AJ, Lu, FK, Xie, XS, Joughin, BA, Reddy, RJ, Peng, S, Abdelmoula, WM, Jackson, PR, Kolluri, A, Kellersberger, KA, Agar, JN, Lauffenburger, DA, Swanson, K, Tran, N, Elmquist, WF, White, FM, Sarkaria, JN & Agar, NYR 2018, 'Integrated mapping of pharmacokinetics and pharmacodynamics in a patient-derived xenograft model of glioblastoma', Nature Communications, vol. 9, no. 1, 4904. https://doi.org/10.1038/s41467-018-07334-3
Randall, Elizabeth C. ; Emdal, Kristina B. ; Laramy, Janice K. ; Kim, Minjee ; Roos, Alison ; Calligaris, David ; Regan, Michael S. ; Gupta, Shiv K. ; Mladek, Ann C. ; Carlson, Brett L. ; Johnson, Aaron J. ; Lu, Fa Ke ; Xie, X. Sunney ; Joughin, Brian A. ; Reddy, Raven J. ; Peng, Sen ; Abdelmoula, Walid M. ; Jackson, Pamela R. ; Kolluri, Aarti ; Kellersberger, Katherine A. ; Agar, Jeffrey N. ; Lauffenburger, Douglas A. ; Swanson, Kristin ; Tran, Nhan ; Elmquist, William F. ; White, Forest M. ; Sarkaria, Jann N ; Agar, Nathalie Y.R. / Integrated mapping of pharmacokinetics and pharmacodynamics in a patient-derived xenograft model of glioblastoma. In: Nature Communications. 2018 ; Vol. 9, No. 1.
@article{72b78ca381db414db1266bd8d0c71a19,
title = "Integrated mapping of pharmacokinetics and pharmacodynamics in a patient-derived xenograft model of glioblastoma",
abstract = "Therapeutic options for the treatment of glioblastoma remain inadequate despite concerted research efforts in drug development. Therapeutic failure can result from poor permeability of the blood-brain barrier, heterogeneous drug distribution, and development of resistance. Elucidation of relationships among such parameters could enable the development of predictive models of drug response in patients and inform drug development. Complementary analyses were applied to a glioblastoma patient-derived xenograft model in order to quantitatively map distribution and resulting cellular response to the EGFR inhibitor erlotinib. Mass spectrometry images of erlotinib were registered to histology and magnetic resonance images in order to correlate drug distribution with tumor characteristics. Phosphoproteomics and immunohistochemistry were used to assess protein signaling in response to drug, and integrated with transcriptional response using mRNA sequencing. This comprehensive dataset provides simultaneous insight into pharmacokinetics and pharmacodynamics and indicates that erlotinib delivery to intracranial tumors is insufficient to inhibit EGFR tyrosine kinase signaling.",
author = "Randall, {Elizabeth C.} and Emdal, {Kristina B.} and Laramy, {Janice K.} and Minjee Kim and Alison Roos and David Calligaris and Regan, {Michael S.} and Gupta, {Shiv K.} and Mladek, {Ann C.} and Carlson, {Brett L.} and Johnson, {Aaron J.} and Lu, {Fa Ke} and Xie, {X. Sunney} and Joughin, {Brian A.} and Reddy, {Raven J.} and Sen Peng and Abdelmoula, {Walid M.} and Jackson, {Pamela R.} and Aarti Kolluri and Kellersberger, {Katherine A.} and Agar, {Jeffrey N.} and Lauffenburger, {Douglas A.} and Kristin Swanson and Nhan Tran and Elmquist, {William F.} and White, {Forest M.} and Sarkaria, {Jann N} and Agar, {Nathalie Y.R.}",
year = "2018",
month = "12",
day = "1",
doi = "10.1038/s41467-018-07334-3",
language = "English (US)",
volume = "9",
journal = "Nature Communications",
issn = "2041-1723",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Integrated mapping of pharmacokinetics and pharmacodynamics in a patient-derived xenograft model of glioblastoma

AU - Randall, Elizabeth C.

AU - Emdal, Kristina B.

AU - Laramy, Janice K.

AU - Kim, Minjee

AU - Roos, Alison

AU - Calligaris, David

AU - Regan, Michael S.

AU - Gupta, Shiv K.

AU - Mladek, Ann C.

AU - Carlson, Brett L.

AU - Johnson, Aaron J.

AU - Lu, Fa Ke

AU - Xie, X. Sunney

AU - Joughin, Brian A.

AU - Reddy, Raven J.

AU - Peng, Sen

AU - Abdelmoula, Walid M.

AU - Jackson, Pamela R.

AU - Kolluri, Aarti

AU - Kellersberger, Katherine A.

AU - Agar, Jeffrey N.

AU - Lauffenburger, Douglas A.

AU - Swanson, Kristin

AU - Tran, Nhan

AU - Elmquist, William F.

AU - White, Forest M.

AU - Sarkaria, Jann N

AU - Agar, Nathalie Y.R.

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Therapeutic options for the treatment of glioblastoma remain inadequate despite concerted research efforts in drug development. Therapeutic failure can result from poor permeability of the blood-brain barrier, heterogeneous drug distribution, and development of resistance. Elucidation of relationships among such parameters could enable the development of predictive models of drug response in patients and inform drug development. Complementary analyses were applied to a glioblastoma patient-derived xenograft model in order to quantitatively map distribution and resulting cellular response to the EGFR inhibitor erlotinib. Mass spectrometry images of erlotinib were registered to histology and magnetic resonance images in order to correlate drug distribution with tumor characteristics. Phosphoproteomics and immunohistochemistry were used to assess protein signaling in response to drug, and integrated with transcriptional response using mRNA sequencing. This comprehensive dataset provides simultaneous insight into pharmacokinetics and pharmacodynamics and indicates that erlotinib delivery to intracranial tumors is insufficient to inhibit EGFR tyrosine kinase signaling.

AB - Therapeutic options for the treatment of glioblastoma remain inadequate despite concerted research efforts in drug development. Therapeutic failure can result from poor permeability of the blood-brain barrier, heterogeneous drug distribution, and development of resistance. Elucidation of relationships among such parameters could enable the development of predictive models of drug response in patients and inform drug development. Complementary analyses were applied to a glioblastoma patient-derived xenograft model in order to quantitatively map distribution and resulting cellular response to the EGFR inhibitor erlotinib. Mass spectrometry images of erlotinib were registered to histology and magnetic resonance images in order to correlate drug distribution with tumor characteristics. Phosphoproteomics and immunohistochemistry were used to assess protein signaling in response to drug, and integrated with transcriptional response using mRNA sequencing. This comprehensive dataset provides simultaneous insight into pharmacokinetics and pharmacodynamics and indicates that erlotinib delivery to intracranial tumors is insufficient to inhibit EGFR tyrosine kinase signaling.

UR - http://www.scopus.com/inward/record.url?scp=85056978659&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056978659&partnerID=8YFLogxK

U2 - 10.1038/s41467-018-07334-3

DO - 10.1038/s41467-018-07334-3

M3 - Article

VL - 9

JO - Nature Communications

JF - Nature Communications

SN - 2041-1723

IS - 1

M1 - 4904

ER -